Paragonix Technologies today announced positive long-term registry results demonstrating improvements after heart transplantation. Results from the GUARDIAN-Heart registry demonstrated statistically significant improvements in 2-year survival following heart transplantation. The analysis consisted of a total of 1,261 U.S. adult patients matched using statistical propensity matching. This created two cohorts of equal baseline characteristics to compare the […]
Transplants
Paragonix begins full U.S. launch of donor lung preservation system
Paragonix Technologies announced today that it began the full commercial launch of its Baroguard donor lung preservation system. Baroguard, a first-of-its-kind system, offers an alternative to the current practices. These practices see donor lungs preserved and transported from an inflated state between donor and recipient. Those current organ recovery techniques fail to reliably maintain and […]
Paragonix announces first human use of donor lung preservation system
Paragonix Technologies announced today that it successfully completed the first-in-human case using its new donor lung preservation technology. Waltham, Massachusetts-based Paragonix received FDA clearance for the BAROguard donor lung preservation system in August. It offers an alternative to the current practices. These practices see donor lungs preserved and transported from an inflated state between donor […]
Organ transplant tech developer Paragonix opens new U.S. HQ
Paragonix Technologies announced today that it opened its new corporate headquarters in Waltham, Massachusetts. The organ transplant tech company says its expansion reflects continued growth and its commitment to serving clinicians and patients worldwide. Paragonix’s facility features state-of-the-art R&D laboratories and collaborative spaces. It aims to foster innovation and teamwork across departments in the evolving […]
Paragonix wins FDA clearance for next-gen lung preservation system
Paragonix Technologies announced today that the FDA granted clearance for its next-generation BAROguard donor lung preservation system. BAROguard combines Paragonix’s existing advanced hypothermic preservation technology with automated continuous and active airway pressure control. This ensures that the system maintains an optimal temperature range and a clinically recommended inflation pressure range. It maintains this for donor […]
TransMedics completes Summit Aviation acquisition
TransMedics (Nasdaq:TMDX) announced that it completed its previously announced acquisition of Summit Aviation. Andover, Massachusetts-based TransMedics initially announced its plans to acquire the U.S. charter flight operator on Aug. 1. It did not disclose financial terms at the time. With the closing of the deal, Summit founder Ben Walton joins the company as VP of […]
TransMedics proposes $300M offering
TransMedics (Nasdaq:TMDX) announced today that it intends to offer $300 million in convertible senior unsecured notes. Andover, Massachusetts-based TransMedics develops organ transplant technology. It offers FDA-approved lung and heart transplant technology, such as the OCS Heart that received pre-market approval in April 2022. The company’s offering remains subject to market and other conditions. The notes […]
TransMedics more than doubles revenue in Q1, raises guidance
TransMedics (Nasdaq:TMDX) shares rose this morning on first-quarter results that beat the consensus forecast. Shares of TMDX ticked up 1.2% at $78.78 apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.3%. The Andover, Massachusetts-based organ transplant technology developer posted losses of […]
Study backs Paragonix lung preservation system
Paragonix Technologies announced today that study data demonstrated favorable outcomes related to its LUNGGuard organ preservation system. Cambridge, Massachusetts–based Paragonix evaluated its LUNGGuard against conventional ice-cold storage. The study used real-world, multi-center data collected from the GUARDIAN-Lung Registry. This analysis demonstrated a favorable influence from advanced lung preservation technology on post-transplant outcomes. Paragonix said it […]
Organ preservation tech developer Paragonix raises $24M series B
Paragonix Technologies announced today that it secured $24 million in a Series B financing round. Cambridge, Massachusetts-based Paragonix plans to use the funds to bolster its commercial footprint. That includes the ongoing extension of its clinical service offerings and inventory expansion. The company also plans to use funds to further advance its organ transplant innovations. […]
Baxter, Miromatrix partner on liver failure research
Baxter (NYSE:BAX) and Miromatrix Medical (Nasdaq:MIRO) today announced a collaborative research agreement on acute liver failure (ALF) treatments. As part of the collaboration, Eden Prairie, Minnesota-based Miromatrix created a new liver therapy. The therapy, called MiroLiverELAP, combines a Miromatrix single-use bioengineered liver with Baxter’s PrisMax system. Miromatrix designed the MiroLiverELAP to provide external support to […]